Gyros introduces new CD microlaboratory for Gyrolab MALDI users.


Gyros AB announced today the introduction of a new CD microlaboratory, Gyrolabâ„¢ MALDI IMAC. Maris Hartmanis, President and CEO of Gyros AB explained, “Successful identification of proteins, especially those in low abundance, is crucial in proteomics and detection and identification of phosphorylated proteins is often a particular challenge. Gyrolab MALDI IMAC will offer users a unique solution for detection of phosphorylated peptides by MALDI mass spectrometry.”

This new method offers a smoother, more reliable solution as compared to the mainly manual preparation options currently available. Protein digests are prepared in duplicate (2 x 48) on Gyrolab MALDI IMAC. Phosphorylated peptides are concentrated, purified and crystallized directly onto MALDI target areas on the CD. Each duplicate sample is subjected to the same process, but with the addition of an enzymatic step that should remove any phosphate groups before crystallization. The CD is transferred to MALDI MS for analysis. Phosphorylated peptides are detected by comparing mass spectra from phosphorylated and dephosphorylated samples. Any shifts in mass indicate that the peaks had contained phosphate groups before the enzymatic treatment.

Gyrolab Workstation controls each run through a specific software method, transferring samples and reagents into the microlaboratory and spinning the CD to drive up to 96 samples in parallel through each preparation step.

Dr. Hartmanis added, “Users of our Gyrolab MALDI solution already see the benefits of Gyrolab MALDI SP1, our first CD microlaboratory that offers two alternative sample preparation methods prior to MALDI MS. We are glad to add a second CD to our Gyrolab MALDI offering. Providing an increasing number of preparation options not only benefits Gyrolab MALDI users, but also demonstrates the flexibility and strength of Gyros technology platform”.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.